SCHEMBL971322

SCHEMBL971322

CC(C)c1ncc2c3c(oc2n1)CN(CC(=O)N1CCN(C2CCC2)CC1)CC3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.39
KCNH2 Q12809 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
ALDH1A1 P00352 5/20 0.33
NPSR1 Q6W5P4 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 5/20 0.32
HPGD P15428 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
HRH3 Q9Y5N1 3/20 0.31
CBX7 O95931 1/20 0.31
CDYL2 Q8N8U2 1/20 0.31
CDYL Q9Y232 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
RAB9A P51151 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969376 0.89 PARP1 (0.40) PARP1TMEM97ALDH1A1NPSR1KDM4E
SCHEMBL967205 0.87 PARP1 (0.39) PARP1ALDH1A1NPSR1L3MBTL1KDM4E
SCHEMBL967866 0.86 PARP1 (0.40) PARP1KCNH2TMEM97ALDH1A1NPSR1
SCHEMBL12920066 0.86 PARP1 (0.40) PARP1KCNH2TMEM97ALDH1A1NPSR1
SCHEMBL969526 0.85 HRH3 (0.39) PARP1ALDH1A1NPSR1KDM4EKMT2A
SCHEMBL967329 0.84 PARP1 (0.39) PARP1TMEM97ALDH1A1NPSR1KDM4E
SCHEMBL967841 0.83 KDM4E (0.39) PARP1ALDH1A1KDM4EHRH3CBX7
SCHEMBL967576 0.82 PARP1 (0.42) PARP1ALDH1A1NPSR1KDM4EHPGD
SCHEMBL971597 0.82 PARP1 (0.39) PARP1KCNH2TMEM97ALDH1A1NPSR1
SCHEMBL969868 0.80 PARP1 (0.42) PARP1ALDH1A1NPSR1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885KCNH2 295/4885TMEM97 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.